Tarsus Pharmaceuticals(US:TARS)2026-02-23 21:11Financial Performance - XDEMVY generated net product sales of $151.7 million in Q4 2025 and $451.4 million for the full year 2025, with approximately 130,000 and 400,000 bottles delivered to patients respectively[548]. - Total revenues for the year ended December 31, 2025, were $451.4 million, a significant increase of $268.4 million (147%) compared to $182.9 million in 2024[568]. - Product sales, net of adjustments, reached $451.4 million in 2025, driven by approximately 400,000 bottles of XDEMVY delivered, compared to 163,000 bottles in 2024[569]. - The net loss for the year ended December 31, 2025, was $66.4 million, a reduction of $49.1 million (43%) compared to a net loss of $115.6 million in 2024[568]. - The provision for income taxes was $2.1 million for 2025, primarily due to state income tax expenses, compared to no provision in 2024[575]. Operating Expenses - Operating expenses increased to $522.3 million in 2025, up $218.8 million (72%) from $303.5 million in 2024[568]. - Research and development expenses rose to $64.3 million in 2025, an increase of $10.9 million (20%) compared to $53.4 million in 2024, primarily due to higher payroll and early-stage program costs[572]. - Selling, general and administrative expenses surged to $427.3 million in 2025, an increase of $190.0 million (80%) from $237.3 million in 2024, largely due to increased marketing and personnel costs[573]. Cash and Financing - As of December 31, 2025, the company had aggregate cash, cash equivalents, and marketable securities of $417.3 million[565]. - The company received $134.8 million in net proceeds from a follow-on public offering in March 2025, selling 2,808,988 shares at $44.50 per share[579]. - Net cash used in operating activities was $12.5 million for the year ended December 31, 2025, primarily due to a net loss of $66.4 million, offset by cash receipts of $734.4 million related to XDEMVY net product sales[599]. - Net cash provided by financing activities was $143.4 million for the year ended December 31, 2025, including $134.8 million from the issuance of common stock[603]. - The company experienced a net increase in cash and cash equivalents of $88.8 million for the year ended December 31, 2025, compared to a decrease of $127.6 million in 2024[598]. Development and Trials - Positive topline results from the Ersa Trial showed statistically significant improvements in Meibomian Gland Secretion Score and the number of glands secreting normal liquid in patients with MGD[549]. - The Galatea Trial for TP-04 demonstrated statistically significant improvements in inflammatory lesions and Investigator's Global Assessment score compared to vehicle at week 12[551]. - The Carpo Trial for TP-05 showed a statistically significant increase in tick mortality compared to vehicle (p<0.001) and was well tolerated[555]. - The company aims to advance the clinical development of TP-04 for ocular rosacea and TP-05 for Lyme disease prophylaxis, with a Phase 2 trial for TP-05 expected to initiate in Q2 2026[556]. - Ongoing discussions with regulatory authorities in Japan and Europe are focused on potential approvals for TP-03, with expected timelines for 2026 and 2027 respectively[560]. Market and Awareness - The direct-to-consumer campaign for XDEMVY has increased unaided awareness of Demodex blepharitis to approximately 25% from 2% at the beginning of the campaign[554]. Future Capital Needs - The company may require additional capital to fully develop product candidates and execute its business strategy, with future capital needs depending on revenue from commercial sales and costs associated with commercialization[591]. - The company has future development milestone payments aggregating up to $11.5 million and commercial milestone payments aggregating up to $341.0 million upon achieving specified milestones[597]. - The company’s operating plans may change, necessitating additional capital to meet operational needs, which could lead to dilution for stockholders if equity securities are issued[592]. Lease Commitments - As of December 31, 2025, the company has lease commitments totaling $28.4 million over a remaining lease term of 9.9 years[594]. Manufacturing Agreements - The company has entered into manufacturing supply agreements for XDEMVY, with contractually obligated minimum purchases totaling $23.8 million from 2026 to 2029[596].